A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).

Eur Respir J · 2023 · PMC9558428 · PMID 36229048

Europe PMC DOI

hedged sentence

0.0090

closest p · 0.2× alpha

0.0090

boldest claim

The sentences

nominally significantp=0.009actually significant

A nominally significant model-adjusted difference of 19.1% (95% CI 5.2–33.1%, p=0.009) was observed in the predefined 70–79 years subgroup, but this was not confirmed in Part 2 (n=350 randomised) where the model-adjusted difference was 0.9% (95% CI −9.3–11.2%, p=0.86).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.